AAM: Congress Should Reject Hatch-Waxman Integrity Act of 2019
WASHINGTON, DC (February 7, 2019) —Generic and biosimilar manufacturers rely on FDA approval to operate their businesses—but the Hatch-Waxman Integrity Act requires that to get it, they must surrender their right to question the validity of suspect drug patents. The Administration and Congress have been vocal about enhancing generic and biosimilar competition to lower prescription […]
Stop Big Pharma Patent Abuse
Big Pharma has consistently created market monopolies at the expense of patients’ health and pocketbooks. The IPR process is one way to stop Big Pharma and provide low-cost generic medicines to patients. Learn more: https://www.stoprxpatentabuse.com/
Pharmaceutical Patent Abuse: To Infinity and Beyond!
New report provides further evidence of patent abuse Our pharmaceutical industry in the United States is predicated on a balance between innovation and access. Brand pharmaceutical companies are rewarded for inventing and developing new treatments and cures that improve the quality of life for everyone. In return for the innovation, current law provides brand pharmaceutical […]
Cotton-McCaskill PACED Act Would Help Patients Gain Access to More Affordable Generics
The bipartisan PACED Act would stop Allergan’s patent abuse Brand pharmaceutical companies are finding new, innovative ways to avoid competition from generic and biosimilar medicines, extend their government-provided monopolies and keep patients paying high drug prices. Look no further than Allergan. In a first-of-its-kind maneuver, Allergan sold its patents on Restasis – an eye medication […]
Seeking Asylum for Its Patents on Tribal Lands: The Latest Brand-Name Drug Company Strategy to Preserve Monopoly Pricing
In September 2017, Allergan, the maker of Restasis, adopted an unprecedented strategy: it paid the St. Regis Mohawk Tribe millions of dollars to rent its tribal sovereign immunity in a blatant effort to shield the patents on Restasis from review. The maneuver has deservedly attracted attention in the media (see The New Yorker and Fortune) […]
Health Care Orgs Urge Congress to Take Close Look at Allergan Deal
AAM has joined nine other prominent health care organizations, including America’s Health Insurance Plans, American Hospital Association and American College of Physicians, to send a letter to Capitol Hill encouraging and applauding congressional oversight of Allergan’s sale of its patent for Restasis® to the St. Regis Mohawk Tribe. There’s a lot of talk in Washington […]
AAM Files Brief to Oppose Pharmaceutical Company Abuse of the Patent System
WASHINGTON, DC (May 18, 2018) –AAM filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit calling on the court to reject gamesmanship of the patent system which keeps prescription drug prices high for patients. In this case, Allergan Inc. has transferred its patents to the St. Regis Mohawk Native American […]
AAM Statement — Restricting Patent Settlements Hurts Patients
Banning Patent Litigation Settlements Will Keep Biosimilars and Generic Drugs Off the Market No Patient Benefit – Only Helps Big Pharma Companies Abusing the Patent System MEDIA ADVISORY “If Congress is committed to delivering on President Trump’s pledge to bring down prescription drug costs, lawmakers must start by ending the shenanigans of brand companies who […]
Anti-Competitive Evergreening Delays Patient Access to More Affordable Generics and Biosimilars
Abusing the patent and regulatory systems to prolong a brand drug’s monopoly— a practice commonly referred to as “evergreening”— is increasingly being used as a tactic to delay patient access to more affordable, FDA-approved generic and biosimilar medicines. AAM President and CEO Chip Davis recently testified that these anti-competitive practices run counter to Congress’s stated […]
